Cargando…

The prognostic value of programmed cell death protein ligand 1 in patients with non-muscle-invasive bladder cancer treated with bacille Calmette–Guérin immunotherapy: Current status

OBJECTIVE: To summarise the current evidence of the significance and prognostic value of programmed cell death protein ligand 1 (PD-L1) expression in patients with non-muscle-invasive bladder cancer (NMIBC) treated with bacille Calmette–Guérin (BCG) immunotherapy. METHODS: A search was conducted in...

Descripción completa

Detalles Bibliográficos
Autores principales: Nowak, Łukasz, Krajewski, Wojciech, Poterek, Adrian, Śliwa, Anna, Zdrojowy, Romuald
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7954482/
https://www.ncbi.nlm.nih.gov/pubmed/33763250
http://dx.doi.org/10.1080/2090598X.2020.1791562
_version_ 1783664088976457728
author Nowak, Łukasz
Krajewski, Wojciech
Poterek, Adrian
Śliwa, Anna
Zdrojowy, Romuald
author_facet Nowak, Łukasz
Krajewski, Wojciech
Poterek, Adrian
Śliwa, Anna
Zdrojowy, Romuald
author_sort Nowak, Łukasz
collection PubMed
description OBJECTIVE: To summarise the current evidence of the significance and prognostic value of programmed cell death protein ligand 1 (PD-L1) expression in patients with non-muscle-invasive bladder cancer (NMIBC) treated with bacille Calmette–Guérin (BCG) immunotherapy. METHODS: A search was conducted in May 2020 of three electronic databases; MEDLINE, Scopus, and EMBASE. In this review we included results from original studies investigating the relationship between the PD-L1 expression and BCG response in patients with NMIBC. RESULTS: Only five relevant articles were identified in the literature to date. Some studies showed an association between increased PD-L1 expression and BCG unresponsiveness; however, other authors provided contradictory results and suggested that PD-L1 evaluation could not be used for reliable prediction of BCG response. CONCLUSIONS: The value of PD-L1 evaluation in predicting BCG response is debatable. Current evidence, based only on retrospective analyses, is inconsistent. Comparability of the results is diminished by the methodological limitations of immunohistochemistry assessment. Further multicentre, randomised trials are needed to make definitive conclusions. ABBREVIATIONS: ICs: immune cells; IHC: immunohistochemical staining; (N)MIBC: (non-) muscle-invasive bladder cancer; PD-L1: programmed cell death protein ligand 1; PD-1: programmed cell death protein 1; RC: radical cystectomy; TCs: tumour cells.
format Online
Article
Text
id pubmed-7954482
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Taylor & Francis
record_format MEDLINE/PubMed
spelling pubmed-79544822021-03-23 The prognostic value of programmed cell death protein ligand 1 in patients with non-muscle-invasive bladder cancer treated with bacille Calmette–Guérin immunotherapy: Current status Nowak, Łukasz Krajewski, Wojciech Poterek, Adrian Śliwa, Anna Zdrojowy, Romuald Arab J Urol Management of NMIBC OBJECTIVE: To summarise the current evidence of the significance and prognostic value of programmed cell death protein ligand 1 (PD-L1) expression in patients with non-muscle-invasive bladder cancer (NMIBC) treated with bacille Calmette–Guérin (BCG) immunotherapy. METHODS: A search was conducted in May 2020 of three electronic databases; MEDLINE, Scopus, and EMBASE. In this review we included results from original studies investigating the relationship between the PD-L1 expression and BCG response in patients with NMIBC. RESULTS: Only five relevant articles were identified in the literature to date. Some studies showed an association between increased PD-L1 expression and BCG unresponsiveness; however, other authors provided contradictory results and suggested that PD-L1 evaluation could not be used for reliable prediction of BCG response. CONCLUSIONS: The value of PD-L1 evaluation in predicting BCG response is debatable. Current evidence, based only on retrospective analyses, is inconsistent. Comparability of the results is diminished by the methodological limitations of immunohistochemistry assessment. Further multicentre, randomised trials are needed to make definitive conclusions. ABBREVIATIONS: ICs: immune cells; IHC: immunohistochemical staining; (N)MIBC: (non-) muscle-invasive bladder cancer; PD-L1: programmed cell death protein ligand 1; PD-1: programmed cell death protein 1; RC: radical cystectomy; TCs: tumour cells. Taylor & Francis 2020-07-16 /pmc/articles/PMC7954482/ /pubmed/33763250 http://dx.doi.org/10.1080/2090598X.2020.1791562 Text en © 2020 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group. https://creativecommons.org/licenses/by/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) ), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Management of NMIBC
Nowak, Łukasz
Krajewski, Wojciech
Poterek, Adrian
Śliwa, Anna
Zdrojowy, Romuald
The prognostic value of programmed cell death protein ligand 1 in patients with non-muscle-invasive bladder cancer treated with bacille Calmette–Guérin immunotherapy: Current status
title The prognostic value of programmed cell death protein ligand 1 in patients with non-muscle-invasive bladder cancer treated with bacille Calmette–Guérin immunotherapy: Current status
title_full The prognostic value of programmed cell death protein ligand 1 in patients with non-muscle-invasive bladder cancer treated with bacille Calmette–Guérin immunotherapy: Current status
title_fullStr The prognostic value of programmed cell death protein ligand 1 in patients with non-muscle-invasive bladder cancer treated with bacille Calmette–Guérin immunotherapy: Current status
title_full_unstemmed The prognostic value of programmed cell death protein ligand 1 in patients with non-muscle-invasive bladder cancer treated with bacille Calmette–Guérin immunotherapy: Current status
title_short The prognostic value of programmed cell death protein ligand 1 in patients with non-muscle-invasive bladder cancer treated with bacille Calmette–Guérin immunotherapy: Current status
title_sort prognostic value of programmed cell death protein ligand 1 in patients with non-muscle-invasive bladder cancer treated with bacille calmette–guérin immunotherapy: current status
topic Management of NMIBC
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7954482/
https://www.ncbi.nlm.nih.gov/pubmed/33763250
http://dx.doi.org/10.1080/2090598X.2020.1791562
work_keys_str_mv AT nowakłukasz theprognosticvalueofprogrammedcelldeathproteinligand1inpatientswithnonmuscleinvasivebladdercancertreatedwithbacillecalmetteguerinimmunotherapycurrentstatus
AT krajewskiwojciech theprognosticvalueofprogrammedcelldeathproteinligand1inpatientswithnonmuscleinvasivebladdercancertreatedwithbacillecalmetteguerinimmunotherapycurrentstatus
AT poterekadrian theprognosticvalueofprogrammedcelldeathproteinligand1inpatientswithnonmuscleinvasivebladdercancertreatedwithbacillecalmetteguerinimmunotherapycurrentstatus
AT sliwaanna theprognosticvalueofprogrammedcelldeathproteinligand1inpatientswithnonmuscleinvasivebladdercancertreatedwithbacillecalmetteguerinimmunotherapycurrentstatus
AT zdrojowyromuald theprognosticvalueofprogrammedcelldeathproteinligand1inpatientswithnonmuscleinvasivebladdercancertreatedwithbacillecalmetteguerinimmunotherapycurrentstatus
AT nowakłukasz prognosticvalueofprogrammedcelldeathproteinligand1inpatientswithnonmuscleinvasivebladdercancertreatedwithbacillecalmetteguerinimmunotherapycurrentstatus
AT krajewskiwojciech prognosticvalueofprogrammedcelldeathproteinligand1inpatientswithnonmuscleinvasivebladdercancertreatedwithbacillecalmetteguerinimmunotherapycurrentstatus
AT poterekadrian prognosticvalueofprogrammedcelldeathproteinligand1inpatientswithnonmuscleinvasivebladdercancertreatedwithbacillecalmetteguerinimmunotherapycurrentstatus
AT sliwaanna prognosticvalueofprogrammedcelldeathproteinligand1inpatientswithnonmuscleinvasivebladdercancertreatedwithbacillecalmetteguerinimmunotherapycurrentstatus
AT zdrojowyromuald prognosticvalueofprogrammedcelldeathproteinligand1inpatientswithnonmuscleinvasivebladdercancertreatedwithbacillecalmetteguerinimmunotherapycurrentstatus